NDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Apr 2016
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 15h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PHOTREXA VISCOUS IN DEXTRAN 20%/PHOTREXA is a riboflavin 5-phosphate ophthalmic solution indicated for corneal cross-linking procedures. It is administered topically as eye drops to prepare the cornea for UV-A light exposure in corneal ectasia treatment. The product works by enabling photochemical strengthening of corneal collagen through riboflavin-mediated cross-linking.
Peak
Product is in peak commercial stage with moderate competitive pressure (30%), indicating stable team size and established commercial infrastructure at Glaukos.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PHOTREXA offers exposure to the specialized ophthalmology market and procedural/clinical positioning, with a focus on building adoption among corneal specialists. Career growth is tied to procedure volume expansion and competitive differentiation in cross-linking technology.
Brand ManagerField Sales Representative
Worked on PHOTREXA VISCOUS IN DEXTRAN 20%/PHOTREXA at Glaukos? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.